BioProNET held a symposium at this conference, entitled ‘Implications of synthetic biology for bioprocessing’ that featured the following presentations:
‘Overview of application of synthetic biology: Cells and Products‘ (Alan Dickson and Mark Smales from BioProNET); ‘Generation of new format biopharmaceuticals: Antibody-drug conjugates‘ (Dave Simpson, Glythera); ‘In vivo/vitro screens for inhibitors of protein aggregation: in disease and biopharmaceuticals?‘ (David Brockwell, University of Leeds); ‘Evaluation of novel format biopharmaceuticals during manufacture‘ (Paul Dalby, University College London).
